Moderna COVID-19 Vaccine: the effective rate of preventing severe illness reaches 100%
Moderna COVID-19 Vaccine: the effective rate of preventing severe illness reaches 100%. Moderna’s COVID-19 vaccine completes Phase 3 clinical efficacy analysis: the effective rate of preventing severe illness reaches 100%
On November 30, Moderna announced that its mRNA technology-based COVID-19 vaccine candidate mRNA-1273 has completed the main efficacy data analysis in the phase 3 clinical trial. At the same time, Moderna announced that it plans to apply to the US FDA for emergency use authorization (EUA) and the European Medicines Agency (EMA) for conditional approval.
A total of 30,000 subjects were recruited for this trial. The main efficacy analysis of 196 symptomatic COVID-19 cases showed that the vaccine’s effective rate of protecting symptomatic COVID-19 was 94.1%.
All 30 severe COVID-19 cases appeared in the control group, which means that this vaccine is 100% effective in preventing severe COVID-19 cases.
In terms of age, race and ethnicity, and gender demographics, the effects are consistent. The 196 cases of COVID-19 included 33 elderly (65 years and older) and 42 participants from different ethnic groups (including 29 Hispanic or Latino, 6 Black or African American, and 4 Asian American And 3 multi-ethnic participants).
The safety of the phase 3 study of mRNA-1273 is under continuous review, and no new serious safety issues have been found.
According to previous analysis, the most common adverse reactions include pain at the injection site, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. After the second administration, the frequency and severity of spontaneous adverse reactions in the mRNA-1273 group increased.